GSK3640254与多替拉韦在健康成人中的I期药代动力学与耐受性评估
本研究为I期开放标签自身对照研究,16名健康受试者依次接受多替拉韦50 mg每日一次、GSK3640254 200 mg每日一次及两药联用,评估药代动力学与耐受性。结果显示联用未显著改变多替拉韦或GSK3640254的稳态暴露,耐受性良好,提示无临床显著药物相互作用。
要点
- 两药联用后多替拉韦AUC、Cmax、Ctrough的GMR分别为1.17、1.09、1.24,均接近1。
- GSK3640254联用后AUC、Cmax、Ctrough的GMR分别为1.04、0.99、0.10。
- 联用未观察到临床显著的耐受性或安全性趋势异常。
核心结论
- GSK3640254与多替拉韦联用未导致临床显著药物相互作用。
- 两药联用耐受性良好,支持进一步评估两药联合方案。
研究设计与样本
- I期研究纳入健康受试者,共16人完成研究。
- 受试者依次接受多替拉韦50 mg QD(第1-5天)、GSK3640254 200 mg QD(第1-7天)及两药联用(第1-7天)。
- 所有药物均在给药前30分钟与中等脂肪餐同服。
主要发现
- 多替拉韦稳态AUC、Cmax、Ctrough的GMR(90%CI)分别为1.17(1.118-1.233)、1.09(1.044-1.138)、1.24(1.160-1.315)。
- GSK3640254稳态AUC、Cmax、Ctrough的GMR(90%CI)分别为1.04(0.992-1.094)、0.99(0.923-1.065)、0.10(0.939-1.056)。
- 未观察到临床显著的耐受性或安全性趋势异常。
关键数值与推荐
- 多替拉韦50 mg QD与GSK3640254 200 mg QD联用时,稳态AUC、Cmax、Ctrough的GMR(90%CI)分别为1.17(1.118-1.233)、1.09(1.044-1.138)、1.24(1.160-1.315)。
- GSK3640254联用后稳态AUC、Cmax、Ctrough的GMR(90%CI)分别为1.04(0.992-1.094)、0.99(0.923-1.065)、0.10(0.939-1.056)。
临床怎么用
- 该I期研究提示两药联用无需基于药代动力学进行剂量调整。
- 临床用药仍需结合患者个体情况及后续研究数据综合评估。
局限性
- 本研究为I期健康受试者研究,样本量较小(16人完成)。
- 研究仅在健康成人中评估,未涉及HIV感染者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: GSK3640254, a novel, next-generation maturation inhibitor effective against a range of HIV polymorphisms with no cross-resistance to current antiretroviral therapy, could potentially be coadministered with dolutegravir as a 2-drug regimen. In this phase I study, pharmacokinetics and tolerability of GSK3640254 plus dolutegravir were assessed. METHODS: Healthy participants received dolutegravir 50 mg once daily (QD) on Days 1-5 in period 1, GSK3640254 200 mg QD on Days 1-7 in period 2, and dolutegravir 50 mg plus GSK3640254 200 mg QD on Days 1-7 in period 3. All treatments were administered with a moderate-fat meal 30 minutes prior to dosing. Pharmacokinetics parameters were derived by noncompartmental methods, and geometric mean ratios (GMRs) and 90% confidence intervals (CIs) were derived using linear mixed effects models. Adverse events, laboratory measurements, electrocardiography and vital signs were monitored. RESULTS: Sixteen participants completed the study. GMRs (90% CIs) for dolutegravir area under the plasma concentration-time curve from time 0 to the end of the dosing interval at steady state, maximum observed concentration and plasma concentration at the end of the dosing interval were 1.17 (1.118-1.233), 1.09 (1.044-1.138) and 1.24 (1.160-1.315), respectively. The GMRs (90% CIs) for GSK3640254 were 1.04 (0.992-1.094), 0.99 (0.923-1.065) and 0.10 (0.939-1.056), respectively. Dolutegravir plus GSK3640254 coadministration did not meaningfully alter steady-state exposure to dolutegravir or GSK3640254. No clinically significant trends in tolerability or safety were observed. CONCLUSION: Coadministration of GSK3640254 with dolutegravir did not result in clinically significant drug interaction and was well tolerated.
引用
- Pene Dumitrescu T, Joshi SR, Xu J, et al. Phase I evaluation of pharmacokinetics and tolerability of the HIV-1 maturation inhibitor GSK3640254 and dolutegravir in healthy adults. Br J Clin Pharmacol. 2021. PMID: 33533507. doi:10.1111/bcp.14759
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。